Results 231 to 240 of about 189,147 (282)

Use of a Molecular Signature Response Classifier to Inform Treatment Selection Improves Clinical Disease Activity Among Patients with Rheumatoid Arthritis Initiating a Biologic or Targeted Synthetic Disease‐Modifying Antirheumatic Drug

open access: yesArthritis Care &Research, EarlyView.
Objective We assessed the effectiveness of PrismRA to improve clinical outcomes among patients with rheumatoid arthritis (RA) initiating treatment with a biologic or targeted synthetic disease‐modifying antirheumatic drug (b/tsDMARD). Methods PrismRA incorporated 19 gene expression features and four clinical features to assess a patient's likelihood of
Fenglong Xie   +3 more
wiley   +1 more source

CD36-PPARγ-SPP1 axis mediates hepatocyte-macrophage coordination to drive MASLD-related liver fibrosis. [PDF]

open access: yesJHEP Rep
Dai Z   +12 more
europepmc   +1 more source

High-level prodigiosin production in <i>Pseudomonas putida</i> enabled by combinatorial metabolic engineering. [PDF]

open access: yesSynth Syst Biotechnol
Zhang Y   +7 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy